SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
SPL026 (N,N-dimethyltryptamine [DMT] fumarate) is a psychedelic tryptamine being developed as
a therapy for patients with major depressive disorder (MDD).